Myriad Genetics (MYGN) stock plummeted over 25% in pre-market trading on Tuesday, following the company's fourth-quarter 2024 earnings report and conference call. The decline was primarily driven by weaker-than-expected first-quarter 2025 guidance and concerns over the impact of UnitedHealthcare's decision not to cover the company's GeneSight pharmacogenomic test.
For the fourth quarter, Myriad Genetics reported adjusted earnings per share of $0.03, in line with analysts' expectations. Revenue of $210.6 million also narrowly missed the consensus estimate of $211.6 million. However, the company's guidance for the first quarter of 2025 significantly missed expectations, with an anticipated adjusted loss per share of $(0.04)-(0.08) compared to the consensus estimate of $(0.03).
Myriad Genetics maintained its full-year 2025 adjusted EPS guidance of $0.07-$0.11, in line with analysts' expectations. However, the weaker-than-expected first-quarter guidance and the potential impact of UnitedHealthcare's decision not to cover the company's GeneSight test weighed heavily on the stock. Analysts at UBS also cut their price target on the stock to $16 from $18, citing concerns over the UnitedHealthcare headwinds.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。